Cell Therapeutics (CTIC) 2.87 $CTIC
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -
PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders
at The Street - Mon Mar 31, 9:45AM CDT
Stocks with insider trader activity include CTIC, KR and IBKR
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Stock to Watch: Cell Therapeutics Down 5.5% (CTIC)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.5% to $3.60 on 1.3x average daily volume. Cell Therapeutics has traded 6.6 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.2%) and underperformed the S&P 500 (-5.5% to the S&P's -0.6%) during today's trading.
What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx
PR Newswire - Fri Mar 14, 7:54AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Cell Therapeutics Inc. (NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc. (NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on these four companies can be accessed at:
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS
Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:
Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.
Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.
PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -
PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.
Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:
Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...
Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.
Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders
at The Street - Mon Mar 31, 9:45AM CDT
Stocks with insider trader activity include CTIC, KR and IBKR
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.
Stock to Watch: Cell Therapeutics Down 5.5% (CTIC)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.5% to $3.60 on 1.3x average daily volume. Cell Therapeutics has traded 6.6 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.2%) and underperformed the S&P 500 (-5.5% to the S&P's -0.6%) during today's trading.
What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx
PR Newswire - Fri Mar 14, 7:54AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Cell Therapeutics Inc. (NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc. (NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on these four companies can be accessed at:
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS
Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
